Latest Urology News

Natural Treatment and Maintenance of Prostate Enlargement with New Thermobalancing Therapy Improves Men’s Well-being in Safety States Fine TreatmentFine Treatment recommends new Thermobalancing Therapy as successful natural solution for benign prostatic hyperplasia that is also the most cost-effective prostate treatment on the market. While long-term medication courses and BPH surgeries may cost thousands of dollars, the price of Dr. Allen’s Device for Prostate Treatment under $150 makes it widely affordable. London, UK (PRWEB) May 26, 2012...

Joy Keys Chats with the Faces of Stroke AmbassadorsPhiladelphia, PA, May 26, 2012 --(PR.com)-- Faces of Stroke Ambassadors Date: May 26th, 2012 Time: 11:00 a.m. – 11:30 a.m. ET Call In Number: 646-929-0368. Url: http://www.blogtalkradio.com/joykeys/2012/05/26/joy-keys-chats-with-the-faces-of-stroke-ambassadors Lenice Hogan: Hogan is a survivor of not one stroke, but three, all at young ages. She survived hemorrhagic strokes at the ages...

'American Idol' Winner Undergoes Surgeries During ContestBy Celebrity Diagnosis We all know that "American Idol" can be a grueling experience for its contestants. But imagine undergoing eight surgical procedures over the course of it... We were aware that Season 11 winner Philip Phillips had bee...

Saw palmetto no better than placebo in men with BPHNEW YORK (Reuters Health) - Saw palmetto, a fruit extract some men take to relieve the symptoms of an enlarged prostate, is no more effective than a sugar pill, according to the latest review of research on the herbal remedy.

Endo Health Solutions Inc. to Present at Jefferies 2012 Global Healthcare ConferenceCHADDS FORD, Pa., May 25, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Julie McHugh, chief operating officer, will present a corporate overview at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012 at 9:00 a.m. ET. The conference will be held in New York City. A live webcast and audio archive of the presentation will be availa...

Endo Health Solutions Inc. to Present at the Goldman Sachs 33rd Annual Global Healthcare ConferenceCHADDS FORD, Pa., May 25, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Alan Levin, executive vice president and chief financial officer, will present a corporate overview at the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5, 2012 at 2:40 p.m. PT. The conference will be held at Terranea in Rancho Palos Verdes, CA. A live webc...

Enzalutamide Is a 'Game Changer' in Prostate CancerAUA 2012: Enzalutamide, an androgen-receptor signaling inhibitor, improves survival in postdocetaxel prostate cancer, according to a phase 3 study. Medscape Medical News

Watson to Present at the Jefferies 2012 Global Healthcare ConferencePARSIPPANY, N.J., May 25, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Siggi Olafsson, Watson's President of Global Generics, will provide an overview and update of the Company's business at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012 at 11:00AM Eastern Time at the G...

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate)NEW BRUNSWICK, N.J., May 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Ill. Results from pre-specified interim analyses of COU-AA-3...

New prostate cancer screening guidelines face a tough sell, study suggests(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback fro...

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meetingDiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the...

BPH Symptoms Can Be Improved with New Thermobalancing Therapy Without Potentially Harmful Drugs & Prostate Surgeries, Reveals Fine TreatmentThe improvement to BPH symptoms with the use of new Thermobalancing Therapy comes gradually; for instance, the urinary symptoms at first ease during the day and later in the night, Fine Treatment highlights. This therapy decreases the size of the enlarged prostate naturally without resorting to potentially harmful BPH drugs and prostate surgeries. London, UK (PRWEB) May 25, 2012 With the new Ther...

Towards an understanding of the genetic basis of prostate cancer

PCA3 Test Featured at American Urological Association MeetingDiagnoCure Management Responds to USPSTF Recommendation on Prostate Cancer Screening Ticker Symbol: CUR QUEBEC CITY, May 25, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and di...

Doctors disagree on new prostate cancer screening guidelinesOne doctor suggests the problem is the rush to treatment, not the screening; another suggests that a failure to screen men could be more costly in the long run.

Early baldness may be a risk factor for prostate cancerNEW YORK (Reuters Health) - Male pattern baldness may be an independent risk factor for prostate cancer, according to new research presented at the 107th Annual Scientific Meeting of the American Urological Association (AUA).

Why People Stick with Cancer Screening, Even When It Causes HarmThe data on PSA testing to detect prostate cancer has long been shaky -- so much so that the discoverer of PSA (or prostate-specific antigen, an enzyme made by the prostate) himself decried the test two years ago as "hardly more effective than a coin...

Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting- Presentations highlight first oral proteasome inhibitor in clinical trials in multiple myeloma patients -CAMBRIDGE, Mass., May 23, 2012 – with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the American Socie...

Obesity Epidemic Likely Cause Of Huge Increase In Kidney StonesThe number of Americans suffering from kidney stones between 2007 and 2010 nearly doubled since 1994, according to a study by researchers at the University of California, Los Angeles (UCLA) and RAND. "While we expected the prevalence of kidney stones...

Why I decided to get a PSA screening test for prostate cancerI’m a big believer in avoiding over-testing and over-treatment. So it might surprise you that I opted to undergo prostate-specific antigen (PSA) screening for prostate cancer right around the time that the US Preventive Services Task Force reco...

Watson Confirms Testim® Patent ChallengePARSIPPANY, N.J., May 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim&...

Uroplasty Announces Product Development and New Clinical Trial InitiativesMINNEAPOLIS, May 24, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of patients with voiding dysfunctions, today announced two new research and development initiatives to expand its commitment to using the Company's neuromodulation technology to treat voiding dysfunctions. ...

Hisamitsu Pharma Submits NDA For Oxybutynin In JapanHisamitsu Pharma is aiming for 2013 approval of Oxybutynin, the fourth drug being developed for overactive bladder in Japan.

Dr. Kevin Howell Selected For Patients' Choice Award 2011Dr. Kevin Howell of Grand Junction, CO has been ranked among the top physicians in the nation based on patient reviews. GRAND JUNCTION, Colo., May 24, 2012 /PRNewswire-USNewswire/ -- A select few physicians were honored with the prestigious 2011 Patients' Choice Award, and this year they include Dr. Kevin Howell. (Photo: http://photos.prnewswire.com/prnh/20120524/DC13423 ) Only doc...

Psychological Aspects of Prostate CancerWhich issues most affect the psychological well-being of prostate cancer patients -- and what is the best way to support these patients and their caregivers? Prostate Cancer and Prostatic Diseases

0 1 2 3 4 ›»

buy Urology market research data and corporate reports now Advertisement